Lacking awareness of metabolic dysfunction-associated steatohepatitis (MASH) constitutes a critical barrier for enhancing patient care, said Naim Alkhouri, MD. Awareness efforts can not only increase ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

The liver, often underappreciated, plays vital roles and faces unique challenges in women due to hormonal, metabolic, and ...

Recent study analyzed postoperative liver dysfunction following lung transplantation with extracorporeal life support and its ...

Mar. 24, 2025 — A comprehensive study shows that people with fatty liver disease have almost twice the mortality rate of the general population. They have an increased risk of dying from both ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition ...

To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Giloy, a popular herb in Ayurvedic medicine, gained prominence during the COVID-19 pandemic for its immunity-boosting ...

According to a 2018 article, at least 25 percent of adults have metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease.

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a common liver disease that ...